Fulvestrant-induced toxic epidermal necrolysis
An. bras. dermatol
;
94(2): 218-220, Mar.-Apr. 2019. tab, graf
Article
in English
| LILACS
| ID: biblio-1001152
ABSTRACT
Abstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Skin
/
Stevens-Johnson Syndrome
/
Estrogen Receptor Antagonists
/
Fulvestrant
Limits:
Female
/
Humans
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2019
Type:
Article
Affiliation country:
Spain
Institution/Affiliation country:
University Hospital Virgen Macarena/ES
Similar
MEDLINE
...
LILACS
LIS